Article

High-risk prostate cancer: Video resources

Our January 2015 installment in the ongoing "New Frontiers in Prostate Cancer" series focuses on the challenges presented by high-risk disease. Here are some video resources on high-risk prostate cancer.

Our January 2015 installment in the ongoing "New Frontiers in Prostate Cancer" series focuses on the challenges presented by high-risk disease. Here are some video resources on high-risk prostate cancer.

1. Treating high-risk localized prostate cancer (OncLive)

Next: New data on RT in high-risk prostate cancer

 

2. New data on RT in high-risk prostate cancer (MedPage Today)

3. Two genes together drive aggressive prostate cancer (Columbia University Medical Center)

Subscribe to Urology Times to get monthly news from the leading news source for urologists.
 

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Alexander Pastuszak, MD, PhD: Is hormone therapy safe after prostate cancer radiotherapy?
Refining prostate cancer therapy strategy to address RAPTOR findings
Related Content
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
October 14th 2024

Lisa F. Newcomb, PhD, on active surveillance for prostate cancer

Lisa F. Newcomb, PhD
"My hope is that the results of our study improve the uptake of active surveillance, further reducing unnecessary treatments, and this, combined with the improving reflex tests, may change the risk-benefit of PSA screening," says Lisa F. Newcomb, PhD.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
October 10th 2024

Talazoparib/enzalutamide significantly boosts OS in mCRPC

Benjamin P. Saylor Jason M. Broderick Conor Killmurray
"The TALAPRO-2 results provide much-needed hope to patients who remain in high unmet need for effective treatment options," said Neeraj Agarwal, MD, FASCO.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
FDA approves study of Aquablation vs radical prostatectomy in prostate cancer
October 8th 2024

FDA approves study of Aquablation vs radical prostatectomy in prostate cancer

Hannah Clarke
The WATER IV PCa will assess Aquablation vs radical prostatectomy in patients with grade group 1 to 3 localized prostate cancer.
Apalutamide associated with improved 2-year survival vs enzalutamide in mCSPC
October 2nd 2024

Apalutamide associated with improved 2-year survival vs enzalutamide in mCSPC

Hannah Clarke
At the 24-month time point, patients who received apalutamide had a 23% reduction in the risk of death compared with patients who initiated enzalutamide.
© 2024 MJH Life Sciences

All rights reserved.